160 related articles for article (PubMed ID: 36765365)
1. A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.
Cui J; Chen X; Zhai Q; Chen N; Li X; Zhang Y; Wang H; Bian X; Gao N; Chen D; Chen Z; Zhang S; Chen Y
Diagn Pathol; 2023 Feb; 18(1):19. PubMed ID: 36765365
[TBL] [Abstract][Full Text] [Related]
2. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
4. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
5. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract][Full Text] [Related]
6. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
9. A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.
Devereaux KA; Steiner DF; Ho C; Gomez AJ; Gilks B; Longacre TA; Zehnder JL; Howitt BE; Suarez CJ
Int J Gynecol Pathol; 2022 Nov; 41(6):541-551. PubMed ID: 34907997
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
11. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
[TBL] [Abstract][Full Text] [Related]
12. Fast and reliable Sanger POLE sequencing protocol in FFPE tissues of endometrial cancer.
Laczmanska I; Michalowska D; Jedryka M; Blomka D; Semeniuk M; Czykalko E; Abrahamowska M; Mlynarczykowska P; Chrusciel A; Pawlak I; Maciejczyk A
Pathol Res Pract; 2023 Feb; 242():154315. PubMed ID: 36738508
[TBL] [Abstract][Full Text] [Related]
13. POLE exonuclease domain mutations in endometrial carcinoma: a case report.
Pasciuto MP; Felicioni L; Zampacorta C; Ferro B; Di Marino P; Primavera FC; Lucidi A; Rossetti R; Barbareschi M; Marchetti A; Buttitta F; D'Angelo E
Pathologica; 2023 May; 1(1):181-185. PubMed ID: 37216304
[TBL] [Abstract][Full Text] [Related]
14. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
15. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
Li Y; Bian Y; Wang K; Wan XP
BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
[TBL] [Abstract][Full Text] [Related]
16. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
[TBL] [Abstract][Full Text] [Related]
17. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
19. First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene.
Rosa RCA; Yurchenko AA; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Kannouche PL; Nikolaev S; Ferraz VEF
Genet Mol Biol; 2020; 43(4):e20200100. PubMed ID: 33001133
[TBL] [Abstract][Full Text] [Related]
20. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]